Early stages of amyloid fibril formation studied by liquid-state NMR: The peptide hormone glucagon

Biophysical Journal

Volumn 95, Issue 1, 2008, Pages 366-377

  Svane, Anna Sigrid Pii ^a   Jahn, Kasper ^a   Deva, Taru ^a   Malmendal, Anders ^a   Otzen, Daniel Erik ^a   Dittmer, Jens ^a   Nielsen, Niels Chr ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; GLUCAGON;

ARTICLE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; CRYSTALLIZATION; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHASE TRANSITION; PROTEIN CONFORMATION; SOLUTION AND SOLUBILITY; ULTRASTRUCTURE;

AMYLOID; COMPUTER SIMULATION; CRYSTALLIZATION; GLUCAGON; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; MODELS, MOLECULAR; PHASE TRANSITION; PROTEIN CONFORMATION; SOLUTIONS;

EID: 46749110019     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1529/biophysj.107.122895     Document Type: Article

References (71)

1. Chiti, F., and F. M. Dobson. 2006. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75:333-366.
2. Caughey, B., and P. T. Lansbury Jr. 2003. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26:267-298.
3. Tycko, R. 2006. Molecular structure of amyloid fibrils: insights from solid-state NMR. Q. Rev. Biophys. 39:1-55.
4. Sipe, J. D., and A. S. Cohen. 2000. Review: history of the amyloid fibril. J. Struct. Biol. 130:88-98.
5. Frokjaer, S., and D. E. Otzen. 2005. Protein drug stability: a formulation challenge. Nat. Rev. Drug. Disc. 4:298-306.
6. Dobson, C. M. 2003. Protein folding and misfolding. Nature. 426:884-890.
7. Ellis, R. J., and T. J. T. Pinheiro. 2002. Medicine: danger misfolding proteins. Nature. 416:483-484.
8. Naiki, H., N. Hashimoto, S. Suzuki, H. Kimura, K. Nakakuki, and F. Gejyo. 1997. Establishment of a kinetic model of dialysis-related amyloid fibril extension in vitro. Amyloid. 4:223-232.
9. Serio, T. R., A. G. Cashikar, A. S. Kowal, G. J. Sawicki, J. J. Moslehi, L. Serpell, M. F. Arnsdorf, and S. L. Lindquist. 2000. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science. 289:1317-1321.
10. Uversky, V. N., J. Li, P. Souillac, I. S. Millett, S. Doniach, R. Jakes, M. Goedert, and M. L. Fink. 2002. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of α-synuclein assembly by β- and γ-synucleins. J. Biol. Chem. 277:11970-11978.
11. Pedersen, J. S., G. Christensen, and D. E. Otzen. 2004. Modulation of S6 fibrillation by unfolding rates and gatekeeper residues. J. Mol. Biol. 341:575-588.
12. Zandomeneghi, G., M. R. H. Krebs, M. G. McCammon, and M. Fändrich. 2004. FTIR reveals structural differences between native β-sheet proteins and amyloid fibrils. Protein Sci. 13:3314-3321.
13. Bouchard, M., J. Zurdo, E. J. Nettleton, C. M. Dobson, and C. V. Robinson. 2000. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci. 9:1960-1967.
14. Pedersen, J. S., D. Dikov, J. L. Fink, H. A. Hjuler, G. Christiansen, and D. E. Otzen. 2006. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J. Mol. Biol. 355:501-523.
15. Jimenez, J. L., E. J. Nettleton, M. Bouchard, C. V. Robinson, C. M. Dobson, and H. R. Saibil. 2002. The protofilament structure of insulin amyloid fibrils. Proc. Natl. Acad. Sci. USA. 99:9196-9201.
16. Khurana, R., C. Ionescu-Zanetti, M. Pope, J. Li, L. Nielson, M. Ramirez-Alvarado, L. Regan, A. L. Fink, and S. A. Carter. 2003. A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy. Biophys. J. 85:1135-1144.
17. Glenner, G. G., E. D. Eanes, H. A. Bladen, R. P. Linke, and J. D. Termine. 1974. β-pleated sheet fibrils - comparison of native amyloid with synthetic protein fibrils. J. Histochem. Cytochem. 22:1141-1158.
18. Nelson, R., M. R. Sawaya, M. Balbirnie, A. Ø. Madsen, C. Riekel, R. Grothe, and D. Eisenberg. 2005. Structure of the cross-β spine of amyloid-like fibrils. Nature. 435:773-778.
19. Vestergaard, B., M. Groenning, M. Roessle, J. S. Kastrup, M. Van de Weert, J. M. Flink, S. Frokjaer, M. Gajhede, and D. I. Svergun. 2007. A helical structural nucleus is the primary elongating unit of insulin amyloid fibril. PLoS Biol. 5:e134.
20. Petkova, A. T., Y. Ishii, J. J. Balbach, O. N. Antzutkin, R. D. Leapman, F. Delaglio, and R. Tycko. 2002. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid-state NMR. Proc. Natl. Acad. Sci. USA. 99:16742-16747.
21. Petkova, A. T., R. D. Leapman, Z. Guo, W.-M. Yau, M. P. Mattson, and R. Tycko. 2005. Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science. 307:262-265.
22. Jaroniec, C. P., C. E. MacPhee, V. S. Bajaj, M. T. McMahon, C. M. Dobson, and R. G. Griffin. 2004. High-resolution molecular structure of a peptide in an amyloid fibril determined by magic angle spinning NMR spectroscopy. Proc. Natl. Acad. Sci. USA. 101:711-716.
23. Ritter, C., M. L. Maddelein, A. B. Siemer, T. Luhrs, M. Ernst, B. H. Meier, S. J. Saupe, and R. Riek. 2005. Correlation of structural elements and infectivity of the HET-s prion. Nature. 435:844-848.
24. Heise, H., W. Hoyer, S. Becker, O. C. Andronesi, D. Riedel, and M. Baldus. 2005. Molecular-level secondary structure, polymorphism, and dynamics of full-length α-synuclein fibrils studied by solid-state NMR. Proc. Natl. Acad. Sci. USA. 102:15871-15876.
25. Eanes, E. D., and G. G. Glenner. 1968. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16:673-677.
26. Come, J. H., P. E. Fraser, and P. T. Lansbury, Jr. 1993. A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc. Natl. Acad. Sci. USA. 90:5959-5963.
27. Jarrett, J. T., and P. T. Lansbury, Jr. 1992. Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry. 31:12345-12352.
28. Colon, W., and J. W. Kelly. 1992. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry. 31:8654-8660.
29. Carulla, N., G. L. Caddy, D. R. Hall, J. Zurdo, G. M. Feliz, E. Giralt, C. V. Robison, and C. M. Dobson. 2005. Molecular recycling within amyloid fibrils. Nature. 436:554-558.
30. Andersen, C. B., D. Otzen, G. Christiansen, and C. Rischel. 2007. Glucagon amyloid-like fibril morphology is selected via morphology-dependent growth inhibition. Biochemistry. 46:7314-7324.
31. Chiti, F., M. Stefani, N. Taddei, G. Ramponi, and C. M. Dobson. 2003. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature. 424:805-808.
32. Hartley, D. M., D. M. Walsh, C. P. Ye, T. Diehl, S. Vasquez, P. M. Vassilev, D. B. Teplow, and D. J. Selkoe. 1999. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19:8876-8884.
33. Baskakov, I. V., G. Legname, M. A. Baldwin, S. B. Prusiner, and F. E. Cohen. 2002. Pathway complexity of prion protein assembly into amyloid. J. Biol. Chem. 277:21140-21148.
34. Soto, C., L. Estrada, and J. Castilla. 2006. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem. Sci. 31:150-155.
35. Hovgaard, M. B., M. Dong, D. E. Otzen, and F. Besenbacher. 2007. Quartz crystal microbalance studies of multilayer glucagon fibrillation at the solid-liquid interface. Biophys. J. 93:2162-2169.
36. De Jong, K. L., B. Incledon, C. M. Yip, and M. R. DeFelippis. 2006. Amyloid fibrils of glucagon characterized by high-resolution atomic force microscopy. Biophys. J. 91:1905-1914.
37. Dong, M. D., M. B. Hovgaard, S. L. Xu, D. E. Otzen, and F. Besenbacher. 2006. AFM study of glucagon fibrillation via oligomeric structures resulting in interwoven fibrils. Nanotechnology. 17:4003-4009.
38. Stigsnaes, P., S. Frokjaer, S. Bjerregaard, M. van de Weert, P. Kingshott, and E. H. Moeller. 2007. Characterisation and physical stability of PEGylated glucagon. Int. J. Pharm. 330:89-98.
39. Onoue, S., K. Ohshima, K. Debari, K. Koh, S. Shioda, S. Iwasa, K. Kashimoto, and T. Yajima. 2004. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm. Res. 21:1274-1283.
40. Kimball, C. P., and J. R. Murlin. 1923. Aqueous extracts of pancreas III. Some precipitation reactions of insulin. J. Biol. Chem. 58:337-348.
41. De Duve, C. 1953. Glucagon; the hyperglycaemic glycogenolytic factor of the pancreas. Lancet. 265:99-104.
42. Hall-Boyer, K., G. P. Zaloga, and B. Chernow. 1984. Glucagon: hormone or therapeutic agent? Crit. Care Med. 12:584-589.
43. Beaven, G. H., W. B. Gratzer, and H. G. Davies. 1969. Formation and structure of gels and fibrils from glucagon. Eur. J. Biochem. 11:37-42.
44. Moran, E. C., P. Y. Chou, and G. D. Fasman. 1977. Conformational transitions of glucagon in solution: the a to b transition. Biochem. Biophys. Res. Commun. 77:1300-1306.
45. Sasaki, K., S. Dockerill, D. A. Adamiak, I. J. Tickle, and T. Blundell. 1975. X-ray analysis of glucagon and its relationship to receptor binding. Nature. 257:751-757.
46. 1H nuclear magnetic resonance studies of the molecular conformation of monomeric glucagon in aqueous solution. Eur. J. Biochem. 91:204-214.
47. 1H nuclear magnetic resonance. J. Mol. Biol. 169:921-948.
48. Wagman, M. E., C. M. Dobson, and M. Karplus. 1980. Proton NMR studies of the association and folding of glucagon in solution. FEBS Lett. 119:265-270.
49. Hoshino, M., H. Katou, Y. Hagihara, K. Hasegawa, H. Naiki, and Y. Goto. 2002. Mapping the core of the β (2)-microglobulin amyloid fibril by H/D exchange. Nat. Struct. Biol. 9:332-336.
50. Morris, K. F., and C. S. Johnson. 1992. Diffusion-ordered two-dimensional nuclear magnetic resonance spectroscopy. J. Am. Chem. Soc. 114:3139-3141.
51. Spearman, C. H. 1904. General intelligence objectivity determined and measured. Am. J. Psychol. 15:201-293.
52. The R project for statistical computing. Web-page: http://www.r-project. org/index.html
53. Claessen, D., R. Rink, W. de Jong, J. Siebring, P. de Vreugd, F. G. Boersma, L. Dijkhuizen, and H. A. Wosten. 2003. A novel class of secreted hydrophobic proteins is involved in aerial hyphae formation in Streptomyces coelicolor by forming amyloid-like fibrils. Genes Dev. 17:1714-1726.
54. Ippel, J. H., A. Olofsson, J. Schleucher, E. Lundgren, and S. S. Wijmenga. 2002. Probing solvent accessibility of amyloid fibrils by solution NMR spectroscopy. Proc. Natl. Acad. Sci. USA. 99:8648-8653.
55. Collins, S. R., A. Douglass, R. D. Vale, and J. S. Weissman. 2004. Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol. 2:e321.
56. Smith, J. F., T. P. J. Knowles, C. M. Dobson, C. E. MacPhee, and M. E. Welland. 2006. Characterization of the nanoscale properties of individual amyloid fibrils. Proc. Natl. Acad. Sci. USA. 103:15806-15811.
57. Narayanan, S., and B. Reif. 2005. Characterization of chemical exchange between soluble and aggregated states of β-amyloid by solution-state NMR upon variation of salt conditions. Biochemistry. 44:1444-1452.
58. Mayer, M., and B. Meyer. 1999. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 38:1784-1788.
59. Pawar, A. P., K. F. DuBay, J. Zurdo, F. Chiti, M. Vendruscolo, and C. M. Dobson. 2005. Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 350:379-392.
60. Wishart, D. S., B. D. Sykes, and F. M. Richards. 1992. The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry. 31:1647-1651.
61. Karplus, M. 1959. Contact electron-spin coupling of nuclear magnetic moments. J. Chem. Phys. 30:11-15.
62. Schwarzinger, S., G. J. A. Kroon, T. R. Foss, J. Chung, P. E. Wright, and H. J. Dyson. 2001. Sequence-dependent correction of random coil NMR chemical shifts. J. Am. Chem. Soc. 123:2970-2978.
63. Zhang, Y. Z., Y. Paterson, and H. Roder. 1995. Rapid amide proton exchange rates in peptides and proteins measured by solvent quenching and two-dimensional NMR. Protein Sci. 4:804-814.
64. Kuwata, K., T. Matumoto, H. Cheng, K. Nagayama, T. L. James, and H. Roder. 2003. NMR-detected hydrogen exchange and molecular dynamics simulations provide structural insight into fibril formation of prion protein fragment 106-126. Proc. Natl. Acad. Sci. USA. 100:14790-14795.
65. Dong, J., J. M. Canfield, A. K. Mehta, J. E. Shokes, B. Tian, W. S. Childers, J. A. Simmons, Z. Mao, R. A. Scott, K. Warncke, and D. G. Lynn. 2007. Engineering metal ion coordination to regulate amyloid fibril assembly and toxicity. Proc. Natl. Acad. Sci. USA. 104:13313-13318.
66. 1H NMR studies of copper binding by histidine-containing peptides. Magn. Reson. Chem. 41:877-883.
67. Fernandez-Escamilla, A. M., F. Rousseau, J. Schymkowitz, and L. Serrano. 2004. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat. Biotechnol. 22:1240-1241.
68. Pedersen, J. S., D. Dikov, and D. E. Otzen. 2006. N- and C-terminal hydrophobic patches are involved in fibrillation of glucagon. Biochemistry. 45:14503-14512.
69. Trovato, A., F. Chiti, A. Maritan, and F. Seno. 2006. Insight into the structure of amyloid fibrils from the analysis of globular proteins. PLoS Comp. Biol. 2:e170.
70. Rost, B., and C. Sander. 1993. Prediction of protein secondary structure at better than 70% accuracy. J. Mol. Biol. 232:584-599.
71. Eisenberg, D., R. M. Weiss, T. C. Terwilliger, and W. Wilcox. 1982. Hydrophobic moments and protein structure. Faraday Symp. Chem. Soc. 17:109-120.